'The Top Line': A closer look at the bounty of new drug approvals in 2023

At Fierce Pharma, the arrival of a new year is synonymous with the release of our annual special report on drug approvals. This week on “The Top Line,” Fierce Pharma’s Eric Sagonowsky and Kevin Dunleavy, both instrumental in creating the special report, are breaking down the numbers and sharing key insights into the landscape of drug approvals in 2023. 

To learn more about the topics in this episode: 

To Listen to More Episodes from The Top Line